Clinicians have traditionally categorized PCa diagnoses into low, intermediate, and high-risk categories, considering a combination of Gleason patterns, PSA levels, and clinical stage (Litwin and Tan, 2017). This evidence concerns the gene KLK3 and posterior cortical atrophy.